Havrix

Havrix is an injectable vaccine that contains inactivated hepatitis A virus and the adjuvant algeldrate. It is supplied as a sterile solution for intramuscular use and is marketed in the European Union as a prescription product. Havrix induces active immunity by stimulating antibody production against hepatitis A virus, and it is typically given in a two‑dose series to provide long‑term protection in healthy individuals across age groups.

Havrix is indicated for the prevention of hepatitis A infection in individuals who have not been previously immunized.

- Active immunization of adults and children aged 12 months and older. - Pre‑travel prophylaxis for persons traveling to regions with intermediate or high hepatitis A endemicity. - Post‑exposure prophylaxis when administered within two weeks of exposure. - Use in outbreak settings to quickly establish herd immunity. - Immunization of individuals with chronic liver disease to reduce risk of severe hepatitis A.

The safety profile of Havrix reflects the typical reactions observed with inactivated viral vaccines.

Common: - Mild pain, redness, or swelling at the injection site, usually resolving within a few days. - Low‑grade fever lasting 24–48 hours, sometimes accompanied by chills. - Headache or fatigue that is transient and does not interfere with daily activities. - Muscle aches or joint discomfort that are mild and short‑lived.

Serious: - Severe allergic reaction (anaphylaxis) with symptoms such as difficulty breathing, hives, swelling of the face, throat, or tongue, and a rapid drop in blood pressure, requiring immediate medical attention. - Guillain‑Barré syndrome, a rare immune‑mediated neurological disorder that may cause muscle weakness and paralysis, reported in a very small number of vaccine recipients.

Precautions for Havrix focus on patient history, immune status, and appropriate timing of vaccination.

- Defer vaccination in individuals with known severe allergy to any vaccine component, including algeldrate. - Postpone administration during acute moderate or severe illness until recovery. - Assess immune competence; immunocompromised patients may have reduced antibody response. - Consider age-specific dosing; children under 12 months are not recommended for this vaccine. - Evaluate pregnancy status; vaccine is generally avoided unless benefits outweigh risks. - Review history of Guillain‑Barré syndrome; discuss potential risks with healthcare provider.

Because Havrix is an inactivated vaccine, drug interactions are limited, but certain medications and conditions may affect its efficacy or safety.

Avoid: - Concurrent administration of immunosuppressive agents (e.g., high‑dose corticosteroids) that may blunt the immune response. - Live‑virus vaccines given within four weeks before or after Havrix, as they may interfere with immune priming.

Use with caution: - Antipyretics such as acetaminophen or ibuprofen taken prophylactically, which might reduce antibody titers. - Blood products or immunoglobulins administered within three months, potentially affecting vaccine‑induced immunity. - Chronic liver disease patients; monitor response and consider additional dosing. - Patients receiving chemotherapy should be evaluated for adequate serologic response.